Bioluminescence Ventures

Bioluminescence Ventures, founded in 2022 and based in San Francisco, is a biotechnology venture capital firm dedicated to advancing the future of medicine. The firm invests in innovative companies within the healthcare sector, focusing on translating transformative scientific advancements into next-generation therapies. Bioluminescence Ventures emphasizes four primary areas for investment: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms. By concentrating on these sectors, the firm aims to harness the accelerating pace of biomedical innovation to create significant impacts for patients while achieving strong financial returns.

Kouki Harasaki

Managing Partner

4 past transactions

GEMMABio

Seed Round in 2024
GEMMABio is a therapeutics company dedicated to developing gene therapies for individuals with rare diseases. Its mission is to accelerate research and enhance global access to these life-changing treatments, aiming to bring gene therapy discoveries from the lab to patients worldwide more swiftly and affordably.

Cerevance

Series B in 2024
Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Ensoma

Series B in 2023
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Nido Biosciences

Series B in 2023
Nido Biosciences is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing precision medicines and small-molecule therapeutics for severe neurological and neuromuscular diseases. It employs a functional genomics platform using human cell lines and tailored screens to identify therapeutic targets driven by human genetics, with the aim of addressing the underlying biology of disease and restoring healthy cell function through targeted interventions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.